Chimerix, Inc. (CMRX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chimerix, Inc. (CMRX) trades at $8.54 with AI Score 50/100 (Hold). Chimerix, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Market cap: $801.08M, Sector: Healthcare.
Last analyzed: Feb 8, 2026Chimerix, Inc. (CMRX) Healthcare & Pipeline Overview
Chimerix is a biopharmaceutical innovator leveraging its TEMBEXA smallpox countermeasure revenue to fuel the development of novel oncology therapeutics, including ONC201, ONC206 and ONC212, offering investors a unique blend of stable revenue and high-growth potential in underserved markets.
Investment Thesis
Chimerix presents a notable research candidate due to its unique position as a biopharmaceutical company with both a revenue-generating product (TEMBEXA) and a promising pipeline of oncology therapeutics. The company's focus on underserved markets, such as rare cancers, offers the potential for significant growth. Key value drivers include the continued sales of TEMBEXA, which provides a stable revenue stream to fund the development of its oncology programs. Successful clinical trials and potential FDA approvals for ONC201, ONC206, ONC212, and DSTAT could significantly increase the company's valuation. The company's negative P/E ratio of -16.82 suggests potential for future profitability as its pipeline matures. Upcoming clinical trial results for its oncology programs represent key catalysts for stock appreciation.
Based on FMP financials and quantitative analysis
Key Highlights
- TEMBEXA (brincidofovir) is an approved medical countermeasure for smallpox, providing a stable revenue stream.
- ONC201 targets tumors with the H3 K27M mutation, addressing a critical unmet need in recurrent diffuse midline glioma patients.
- ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, is in Phase I clinical trials for solid tumors.
- ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP, is being developed for solid tumors and hematological malignancies.
- Gross Margin of 100.0% reflects the high value of TEMBEXA sales and efficient cost management.
Competitors & Peers
Strengths
- Approved product (TEMBEXA) generating revenue.
- Promising pipeline of oncology therapeutics.
- Proprietary imipridone platform.
- Experienced management team.
Weaknesses
- Reliance on TEMBEXA for revenue.
- High research and development costs.
- Dependence on clinical trial success.
- Negative profit margin.
Catalysts
- Clinical trial results for ONC201 in recurrent diffuse midline glioma patients.
- Advancement of ONC206 and ONC212 into later-stage clinical trials.
- Continued sales of TEMBEXA to government agencies.
- Potential strategic partnerships and collaborations.
- Regulatory approvals for pipeline assets.
Risks
- Clinical trial failures for pipeline assets.
- Regulatory delays or rejections.
- Competition from other pharmaceutical companies.
- Dependence on government funding for TEMBEXA sales.
- High research and development costs.
Growth Opportunities
- Growth opportunity 1: Expansion of TEMBEXA's market reach. While currently approved as a smallpox countermeasure, TEMBEXA could potentially be used to treat other viral infections. Exploring these additional indications could significantly expand its market size, potentially reaching hundreds of millions of dollars annually. This expansion would require further clinical trials and regulatory approvals, with a timeline of 3-5 years.
- Growth opportunity 2: Successful development and commercialization of ONC201. ONC201 targets tumors with the H3 K27M mutation, a significant unmet need in recurrent diffuse midline glioma patients. If approved, ONC201 could capture a substantial portion of this market, estimated to be worth $500 million annually. Clinical trial results are expected within the next 1-2 years, with potential FDA approval within 3-4 years.
- Growth opportunity 3: Advancement of ONC206 and ONC212 into later-stage clinical trials. These imipridone-based drugs have shown promise in preclinical studies and early clinical trials. Progressing these programs into Phase II and Phase III trials could unlock significant value, potentially leading to blockbuster drugs with annual sales exceeding $1 billion each. This process is expected to take 3-5 years.
- Growth opportunity 4: Strategic partnerships and collaborations. Chimerix could partner with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. These partnerships could provide access to additional funding, expertise, and distribution channels, significantly increasing the company's chances of success. Such partnerships could be established within the next 1-2 years.
- Growth opportunity 5: Expansion into new therapeutic areas. Chimerix could leverage its expertise in drug development to expand into new therapeutic areas beyond oncology. This could include developing treatments for other infectious diseases or autoimmune disorders. This diversification would reduce the company's reliance on its oncology pipeline and create new growth opportunities. This expansion could begin within the next 2-3 years.
Opportunities
- Expansion of TEMBEXA's market reach.
- Successful development and commercialization of ONC201.
- Strategic partnerships and collaborations.
- Expansion into new therapeutic areas.
Threats
- Competition from other pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Changes in government funding for TEMBEXA.
Competitive Advantages
- Patent protection for TEMBEXA and its pipeline of drug candidates.
- Established relationship with government agencies for TEMBEXA sales.
- Proprietary imipridone platform for developing novel oncology therapeutics.
- Expertise in developing and commercializing drugs for niche markets.
About CMRX
Chimerix, Inc., founded in 2000 and headquartered in Durham, North Carolina, is a biopharmaceutical company dedicated to developing and commercializing innovative medicines that enhance the lives of patients facing serious diseases. The company's journey began with a focus on antiviral therapies, leading to the development and approval of TEMBEXA (brincidofovir), a crucial medical countermeasure for smallpox. TEMBEXA functions by inhibiting viral DNA synthesis, providing a critical defense against this potentially devastating disease. Building upon this foundation, Chimerix has expanded its pipeline to include a range of oncology programs targeting difficult-to-treat cancers. These programs include ONC201, which is focused on tumors with the H3 K27M mutation, particularly in recurrent diffuse midline glioma patients. ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, is in Phase I clinical trials for solid tumors, while ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP, is being developed for solid tumors and hematological malignancies. Additionally, Chimerix is developing dociparstat sodium (DSTAT) to combat resistance to chemotherapy in acute myeloid leukemia. Chimerix also has license agreements with Biomedical Advanced Research and Development Authority, Cantex Pharmaceuticals, Inc., and SymBio Pharmaceuticals.
What They Do
- Develop and commercialize medicines for serious diseases.
- Produce TEMBEXA (brincidofovir) as a medical countermeasure for smallpox.
- Develop ONC201 for treating tumors with the H3 K27M mutation.
- Advance ONC206 for treating solid tumors.
- Develop ONC212 for solid tumors and hematological malignancies.
- Develop dociparstat sodium (DSTAT) for acute myeloid leukemia.
Business Model
- Generate revenue through sales of TEMBEXA to government agencies.
- Develop and out-license or co-develop drug candidates with pharmaceutical partners.
- Receive milestone payments and royalties from licensed products.
- Fund research and development through a combination of product revenue, grants, and partnerships.
Industry Context
Chimerix operates within the biotechnology industry, a sector characterized by high innovation and significant growth potential. The market for oncology therapeutics is particularly large and rapidly expanding, driven by an aging population and increasing cancer incidence. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, such as ALBO, ASLN, CDMO, GRCL and HARP, all vying for market share. Chimerix differentiates itself through its focus on niche markets and its unique pipeline of imipridone-based drugs, offering a potential competitive advantage in the treatment of specific cancer subtypes.
Key Customers
- Government agencies (e.g., Biomedical Advanced Research and Development Authority) for TEMBEXA.
- Patients suffering from cancers and other serious diseases.
- Pharmaceutical companies seeking to license or co-develop drug candidates.
CMRX Financials
CMRX Price Today & Live Chart
Chimerix, Inc. (CMRX) stock price: $8.54 (+0.00, +0.00%)
CMRX Latest News
-
Earnings Scheduled For February 29, 2024
benzinga · Feb 29, 2024
-
Earnings Scheduled For November 2, 2023
benzinga · Nov 2, 2023
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Aug 11, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Aug 8, 2023
CMRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMRX.
Price Targets
Wall Street price target analysis for CMRX.
CMRX MoonshotScore
What does this score mean?
The MoonshotScore rates CMRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
CMRX Healthcare Stock FAQ
What does Chimerix, Inc. do?
Chimerix, Inc. is a biopharmaceutical company that focuses on developing and commercializing medicines to address unmet medical needs, particularly in the areas of oncology and infectious diseases. The company's primary revenue source is TEMBEXA, an FDA-approved antiviral for smallpox, which is sold to government entities as a medical countermeasure. Chimerix is also actively developing a pipeline of novel oncology therapeutics, including ONC201, ONC206 and ONC212, which target difficult-to-treat cancers. These drugs are in various stages of clinical development, with the goal of providing new treatment options for patients with limited alternatives.
Is CMRX stock worth researching?
Evaluating CMRX as a potential investment requires considering both its strengths and weaknesses. The company's approved product, TEMBEXA, provides a stable revenue stream, which helps fund the development of its oncology pipeline. However, the company's profitability is currently negative, as reflected in its P/E ratio of -16.82 and negative profit margin of -55220.5%. The success of its pipeline assets, particularly ONC201, ONC206 and ONC212, is crucial for future growth. Positive clinical trial results and potential FDA approvals could significantly increase the company's valuation, making it a potentially attractive investment for risk-tolerant investors.
What are the main risks for CMRX?
Chimerix faces several risks common to biotechnology companies. A primary risk is the potential for clinical trial failures, which could significantly impact the value of its pipeline assets. Regulatory hurdles and potential delays in obtaining FDA approvals also pose a risk. Competition from other pharmaceutical companies developing similar therapies could limit the market share of Chimerix's products. Additionally, the company's reliance on government funding for TEMBEXA sales creates a risk if funding priorities change. High research and development costs could strain the company's financial resources, potentially requiring additional financing.
What are the key factors to evaluate for CMRX?
Chimerix, Inc. (CMRX) currently holds an AI score of 50/100, indicating moderate score. Key strength: Approved product (TEMBEXA) generating revenue. Primary risk to monitor: Clinical trial failures for pipeline assets. This is not financial advice.
How frequently does CMRX data refresh on this page?
CMRX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CMRX's recent stock price performance?
Recent price movement in Chimerix, Inc. (CMRX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Approved product (TEMBEXA) generating revenue. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CMRX overvalued or undervalued right now?
Determining whether Chimerix, Inc. (CMRX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CMRX?
Before investing in Chimerix, Inc. (CMRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update.
- Financial metrics based on the most recent available data.
- Investment decisions should be made based on individual risk tolerance and due diligence.